References
Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.
Wulfert M, Kupper AC, Tapprich C, Bottomley SS, Bowen D, Germing U et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol 2008; 36: 577–586.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765–3776.
Geyh S, Oz S, Cadeddu RP, Frobel J, Bruckner B, Kundgen A et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013; 27: 1841–1851.
Ferrer RA, Wobus M, List C, Wehner R, Schonefeldt C, Brocard B et al. Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica 2013; 98: 1677–1685.
Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012; 26: 1286–1292.
Mallo M, Cervera J, Schanz J, Such E, Garcia-Manero G, Luno E et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011; 25: 110–120.
Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia 2013; 27: 1072–1079.
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.
Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503–3510.
Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004; 18: 113–119.
Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971–1979.
Braulke F, Jung K, Schanz J, Gotze K, Muller-Thomas C, Platzbecker U et al. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. Leuk Res 2013; 37: 900–906.
Acknowledgements
The trial was supported by Celgene, providing the compound, supporting data monitoring and technical processing of bone marrow biopsies. ES wrote the paper, analyzed the data and approved the final version; ArGi performed centralized cytology, contributed essential data and approved the final version; DH performed cytogenetic banding analyses, contributed essential data and approved the final manuscript; GuBu performed centralized histology and approved the final version; UP, FN, KG, RFS, ArGa, FB, ML, AL, PS, UB, NG, GeBu and RH contributed essential data and approved the final version; KS performed cytogenetic banding analyses and approved the final manuscript; MW performed research and approved the final version and UG designed the research, contributed essential data, analyzed the data and approved the final version.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The trial was supported by Celgene, by providing the compound, supporting data monitoring and technical processing of bone marrow biopsies. ES obtained travel grant for attending symposia from Celgene. ArGi obtained personal financial interests from Celgene. DH obtained research support, honorarium and attending symposia from Celgene. UP obtained honoraria and research funding from Celgene. FN obtained honoraria and research funding from Celgene. KG obtained honoraria from Celgene. RFS obtained research support from Celgene. AL obtained research funding from Celgene. KS obtained travel grant for attending symposia from Celgene. GeBu obtained research support, travel grants and honoraria from Celgene. PS obtained financial support for training events from Celgene. NG obtained honoraria and research funding from Celgene. UG obtained speaker honorarium and research support from Celgene. The remaining authors declare no conflicts of interest.
Rights and permissions
About this article
Cite this article
Schuler, E., Giagounidis, A., Haase, D. et al. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia 30, 1580–1582 (2016). https://doi.org/10.1038/leu.2015.340
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.340
- Springer Nature Limited
This article is cited by
-
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Leukemia (2024)
-
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Annals of Hematology (2021)
-
Evolving therapies for lower-risk myelodysplastic syndromes
Annals of Hematology (2020)
-
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial
Annals of Hematology (2017)
-
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q
Annals of Hematology (2016)